Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCaIPEL study in cancer patients with incidental pulmonary embolism treated with dalteparin
2015-001707-31Phase 4Terminated
- Sponsor
- Hull University Teaching Hospitals
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalteparin in pulmonary embolism (PE) and cancer (2 cohorts), sponsored by Hull University Teaching Hospitals. Primary endpoint: Survival at 6 months. Started May 2015; status: terminated.
02
Drugs
dalteparin
03
Conditions
pulmonary embolism (PE)cancer
Beyond the preview
Go deeper on 2015-001707-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001707-31.